Altasciences is pleased to have supported Metsera, Inc., a clinical-stage biopharmaceutical company focused on advancing next-generation treatments for obesity and metabolic diseases, in its nonclinical and early-stage clinical trials. This partnership includes a recent Phase I/II trial of MET-097i, an ultra-long-acting injectable amylin analog and fully biased GLP-1 receptor agonist. In September, Metsera announced positive topline results from the trial conducted at Altasciences’ facility, where MET-097i demonstrated a 7.5% reduction in body weight from baseline by day 36 (one week post-final dose) and a remarkable 380-hour half-life. These promising results paved the way for Metsera to initiate a randomized 16-week Phase II trial of MET-097i.
In addition to clinical trial support, Altasciences provided Metsera with its Proactive Drug Development solution, which included nonclinical services, bioanalysis, contract research organization (CRO) services, and program management for several other therapeutic candidates. Over the past six months, Altasciences successfully completed nonclinical work for MET-233i and MET-002, an oral GLP-1 receptor agonist peptide, enabling Metsera to initiate clinical trials for both programs this year.
“Congratulations to Metsera on this important milestone in the development of MET-097i,” said Ingrid Holmes, Vice President of Global Clinical Operations at Altasciences. “Metsera is a highly valued partner, and we are proud to contribute to their efforts in developing innovative treatments for individuals affected by obesity-related illnesses.”
Obesity is a global health challenge, contributing to numerous serious conditions such as type 2 diabetes, heart disease, and certain cancers. Treatments like MET-097i represent a promising avenue for addressing this complex condition and improving the lives of those impacted.
